Orchid Pharma (ORCHPHARMA) Q1 24/25 earnings summary

Executive summary

• Q1 FY25 sales reached INR 244.4 crore, a 34% year-over-year increase, driven by strategic initiatives and operational efficiency.

• EBITDA for Q1 FY25 was INR 41 crore, up 71% year-over-year, with margin improving to 17% from 13% in Q1 FY24.

• PAT surged to INR 29.1 crore, a 169% increase compared to the same quarter last year.

• Board approved unaudited standalone and consolidated financial results for Q1 FY25, with no deviation in QIP fund usage.

• Launch of Orblicef (enmetazobactam + cefepime) in partnership with Cipla, with both companies marketing under separate brands.

Financial highlights

• Q1 FY25 revenue was INR 244.4 crore, up from INR 182.9 crore in Q1 FY24.

• EBITDA margin improved to 17% from 13% year-over-year.

• Gross margin for Q1 FY25 was 38.5%.

• Interest expenses decreased by 36% to INR 3.5 crore.

• Domestic business contributed 20% of Q1 revenue; exports made up 80%.

Outlook and guidance

• Full-year revenue growth expected to moderate to 20–25%, in line with long-term guidance.

• Management highlighted continued growth momentum and margin improvement for upcoming quarters.

• Orblicef projected to reach INR 100 crore sales in 3–4 years for the AMS division; not expected to hit this in FY25.

• Royalty income from Europe expected to start in Q2 FY25, with cash flow lagging by one quarter.

• Company continues to focus on expansion and capital expenditure, including new manufacturing facilities.